Latest Breaking News On - Endocrine surgery division - Page 1 : vimarsana.com

Growing tiny tumors in the lab for personalized lung cancer treatment

Lung cancer accounts for nearly 20% of annual cancer-related deaths worldwide. According to 2022 statistics from the Swiss Cancer League, nearly 5,000 new cases of lung cancer are reported in Switzerland each year.

SwitzerlandSwissWolfram karenovicsAlfredo addeoLung cancer centerEndocrine surgery divisionSwiss cancer leagueDepartment of surgeryDepartment of medicineHead of the oncology divisionUniversitaires de genStaff physicianProfessor alfredo addeoOncology divisionCancerLung cancer

Researchers cultivate lung tumors to identify optimal personalized treatments

Researchers cultivate lung tumors to identify optimal personalized treatments
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

SwitzerlandGenevaGenèSwissWolfram karenovicsAmanda muegglerAlfredo addeoSwiss cancer leagueLung cancer centerDepartment of surgeryDepartment of medicineEndocrine surgery divisionHead of the oncology divisionStaff physicianProfessor alfredo addeoOncology division

PULSE BIOSCIENCES FIRST STUDY IN A SURGICAL APPLICATION OF NANOSECOND PULSED FIELD ABLATION TECHNOLOGY TO BE FEATURED IN TWO POSTER PRESENTATIONS AT THE AMERICAN THYROID ASSOCIATION ANNUAL MEETING

HAYWARD - Pulse Biosciences, Inc. , a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today.

United statesWashingtonAmericanKevin danahyRalph tufanoStefano spieziaSarasota memorial health care systemPulse biosciences incNasdaqAmerican thyroid associationNanosecond pulsed field ablationThyroid associationEndocrine surgery divisionNapoli ospedale del mareNeck endocrine surgeryMemorial health care

Pulse Biosciences' First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting

First prospective clinical feasibility study suggests nsPFA may be a safe and effective method for treating benign thyroid tumors or nodules .

United statesWashingtonAmericanRalph tufanoStefano spieziaAmerican thyroid associationPulse biosciences incNasdaqPulse biosciencesNanosecond pulsed field ablationEndocrine surgery divisionNapoli ospedale del mareNeck endocrine surgerySarasota memorial health careBenign thyroid nodulesHistological assessment